Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Human Fibrinogen(Guangdong Danxia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Human Fibrinogen(Guangdong Danxia): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Botulinum toxin A (Q-Med) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Botulinum toxin A (Q-Med): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Botulinum toxin A (inibio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Botulinum toxin A (inibio): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
IM19 CAR-T (Imunopharm) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
IM19 CAR-T (Imunopharm): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Y-3(Neurodawn) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Y-3(Neurodawn): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Morphine Sulfate/Naltrexone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Morphine Sulfate/Naltrexone Hydrochloride: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Setogepram Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Setogepram: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bidridistrogene xeboparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Bidridistrogene xeboparvovec: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Dociparstat sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Dociparstat sodium: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Prolgolimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Prolgolimab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nisevokitug Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Nisevokitug: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Deulorlatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Deulorlatinib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.